Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.
Símbolo de cotizaciónSGHT
Nombre de la empresaSight Sciences Inc
Fecha de salida a bolsaJul 15, 2021
Director ejecutivoMr. Paul Badawi
Número de empleados216
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 15
Dirección4040 Campbell Ave,
CiudadMENLO PARK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94025
Teléfono14158890550
Sitio Webhttps://www.sightsciences.com/
Símbolo de cotizaciónSGHT
Fecha de salida a bolsaJul 15, 2021
Director ejecutivoMr. Paul Badawi
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos